Oramed Pharmaceuticals Financials

ORMP Stock  USD 3.25  0.08  2.52%   
Based on the key indicators related to Oramed Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Oramed Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Oramed Pharmaceuticals' Cash And Short Term Investments are relatively stable compared to the past year. As of 02/17/2026, Liabilities And Stockholders Equity is likely to grow to about 187.5 M, while Total Liabilities is likely to drop slightly above 9.3 M.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Oramed Pharmaceuticals Balance Sheet Chart

At this time, Oramed Pharmaceuticals' Cash And Short Term Investments are relatively stable compared to the past year. As of 02/17/2026, Liabilities And Stockholders Equity is likely to grow to about 187.5 M, while Total Liabilities is likely to drop slightly above 9.3 M.
Key indicators impacting Oramed Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.00280.0029
Notably Down
Pretty Stable
Current Ratio23.8122.67
Sufficiently Up
Slightly volatile
The essential information of the day-to-day investment outlook for Oramed Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should research Oramed Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Oramed Pharmaceuticals.

Net Income

(16.33 Million)

  
Build AI portfolio with Oramed Stock

Oramed Pharmaceuticals Stock Summary

Oramed Pharmaceuticals competes with Ovid Therapeutics, Context Therapeutics, Clene, Shattuck Labs, and Coya Therapeutics. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. Oramed Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Foreign Associate
  Israel
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS68403P2039
Business Address1185 Avenue of
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.oramed.com
Phone844 967 2633
CurrencyUSD - US Dollar

Oramed Pharmaceuticals Key Financial Ratios

Oramed Pharmaceuticals Key Balance Sheet Accounts

202120222023202420252026 (projected)
Other Current Liab(1.4M)(191K)1.4M1.5M1.7M1.8M
Retained Earnings(114.9M)(163.1M)(157.6M)(176.6M)(159.0M)(151.0M)
Total Liab11.5M10.5M57.7M9.9M11.4M9.3M
Common Stock424K476K485K480K552K579.6K
Total Assets128.0M161.6M220.6M155.3M178.6M187.5M
Net Debt(76.7M)(39.6M)42.6M(54.0M)(48.6M)(46.2M)
Accounts Payable2.6M2.2M551K789K907.4K824.5K
Cash77.2M40.5M9.1M54.4M62.6M65.7M
Other Current Assets1.2M1.4M537K1.3M1.5M1.6M
Total Current Assets95.3M157.1M162.6M143.2M164.7M172.9M
Short Term Debt130K247K51.3M216K248.4K236.0K
Net Invested Capital115.8M151.8M214.8M146.3M168.2M145.5M
Capital Stock424K476K485K480K552K472.8K
Net Working Capital88.7M151.4M109.4M137.5M158.2M115.0M

Oramed Pharmaceuticals Key Income Statement Accounts

The reason investors look at the income statement is to determine what Oramed Pharmaceuticals' earnings per share (EPS) will be for research and analysis purposes. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, this information can be used for research and educational purposes even though its price per share may not have changed.
202120222023202420252026 (projected)
Operating Income(24.2M)(40.6M)(15.8M)(12.8M)(11.5M)(12.1M)
Ebit(25.1M)(40.6M)7.1M(15.1M)(13.6M)(12.9M)
Research Development21.0M27.6M9.0M6.3M7.3M7.6M
Ebitda(25.0M)(37.0M)7.3M(14.9M)(13.4M)(12.7M)
Income Before Tax(23.0M)(37.7M)5.1M(15.9M)(14.3M)(13.6M)
Net Income(22.2M)(37.8M)5.5M(19.1M)(17.2M)(16.3M)
Income Tax Expense192K(2.9M)100K3.2M2.9M3.0M
Net Interest Income341K3.6M4.6M4.1M4.7M2.9M
Interest Income347K3.6M8.0M5.0M5.7M3.9M
Minority Interest751K1.2M437K43K38.7K36.8K

Oramed Pharmaceuticals Key Cash Accounts

202120222023202420252026 (projected)
Change In Cash57.9M(36.8M)(31.4M)45.4M52.2M54.8M
Free Cash Flow(21.6M)(29.2M)(10.5M)(8.4M)(7.6M)(8.0M)
Capital Expenditures375.0K496.0K254.0K18.0K20.7K19.7K
Net Income(22.2M)(36.6M)5.5M(19.1M)(17.2M)(16.3M)
Other Non Cash Items2.3M8.7M(13.3M)7.3M8.3M8.8M
End Period Cash Flow77.2M40.5M9.1M54.4M62.6M65.7M
Depreciation77K58K196K193K222.0K233.0K
Investments(23.8M)30.2M(73.0M)105.8M121.7M127.8M

Oramed Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Oramed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Oramed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oramed Pharmaceuticals competition to find correlations between indicators driving Oramed Pharmaceuticals's intrinsic value. More Info.
Oramed Pharmaceuticals is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Oramed Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oramed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Oramed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.At this time, Oramed Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 02/17/2026, Tax Provision is likely to grow to about 3.8 M, while Enterprise Value Over EBITDA is likely to drop (2.84).
 2023 2024 2025 2026 (projected)
Interest Income8.0M5.0M5.7M3.9M
Net Interest Income4.6M4.1M4.7M2.9M

Oramed Pharmaceuticals fundamental ratios Correlations

0.330.47-0.490.550.520.330.480.49-0.04-0.460.270.50.090.380.50.280.420.21-0.390.280.54-0.11-0.290.110.25
0.330.49-0.470.450.450.940.440.610.40.00.030.50.090.010.50.980.520.870.00.980.680.12-0.160.10.46
0.470.49-0.940.980.990.450.970.99-0.50.40.810.990.010.60.990.380.970.540.190.370.910.02-0.650.250.9
-0.49-0.47-0.94-0.96-0.97-0.5-0.97-0.940.5-0.45-0.77-0.96-0.22-0.61-0.96-0.33-0.91-0.51-0.14-0.33-0.88-0.090.65-0.43-0.83
0.550.450.98-0.960.990.440.980.97-0.510.350.810.990.10.60.990.320.930.470.110.320.90.03-0.70.340.84
0.520.450.99-0.970.990.440.990.98-0.520.40.820.990.10.630.990.330.940.490.150.320.90.02-0.70.340.86
0.330.940.45-0.50.440.440.450.580.360.120.020.470.430.00.470.880.450.880.00.880.640.19-0.240.380.39
0.480.440.97-0.970.980.990.450.96-0.560.460.840.970.140.630.980.310.920.510.220.30.860.02-0.720.420.85
0.490.610.99-0.940.970.980.580.96-0.390.390.740.990.090.540.990.50.960.640.180.490.940.05-0.640.30.89
-0.040.4-0.50.5-0.51-0.520.36-0.56-0.39-0.56-0.89-0.46-0.01-0.58-0.460.52-0.430.11-0.550.53-0.130.030.41-0.34-0.45
-0.460.00.4-0.450.350.40.120.460.39-0.560.530.380.330.260.38-0.120.410.250.63-0.130.220.2-0.40.510.54
0.270.030.81-0.770.810.820.020.840.74-0.890.530.78-0.010.670.78-0.10.740.260.53-0.110.51-0.04-0.590.370.71
0.50.50.99-0.960.990.990.470.970.99-0.460.380.780.050.61.00.390.970.510.120.380.940.02-0.660.260.89
0.090.090.01-0.220.10.10.430.140.09-0.010.33-0.010.05-0.040.05-0.03-0.050.25-0.01-0.030.070.23-0.30.82-0.06
0.380.010.6-0.610.60.630.00.630.54-0.580.260.670.6-0.040.61-0.080.590.040.19-0.080.440.21-0.290.230.56
0.50.50.99-0.960.990.990.470.980.99-0.460.380.781.00.050.610.390.970.510.120.380.930.02-0.660.260.89
0.280.980.38-0.330.320.330.880.310.50.52-0.12-0.10.39-0.03-0.080.390.430.81-0.061.00.60.09-0.03-0.050.37
0.420.520.97-0.910.930.940.450.920.96-0.430.410.740.97-0.050.590.970.430.510.170.420.920.03-0.510.160.97
0.210.870.54-0.510.470.490.880.510.640.110.250.260.510.250.040.510.810.510.370.810.550.18-0.260.310.48
-0.390.00.19-0.140.110.150.00.220.18-0.550.630.530.12-0.010.190.12-0.060.170.37-0.06-0.140.09-0.030.330.28
0.280.980.37-0.330.320.320.880.30.490.53-0.13-0.110.38-0.03-0.080.381.00.420.81-0.060.590.09-0.03-0.050.36
0.540.680.91-0.880.90.90.640.860.94-0.130.220.510.940.070.440.930.60.920.55-0.140.590.05-0.570.150.83
-0.110.120.02-0.090.030.020.190.020.050.030.2-0.040.020.230.210.020.090.030.180.090.090.050.070.180.03
-0.29-0.16-0.650.65-0.7-0.7-0.24-0.72-0.640.41-0.4-0.59-0.66-0.3-0.29-0.66-0.03-0.51-0.26-0.03-0.03-0.570.07-0.49-0.43
0.110.10.25-0.430.340.340.380.420.3-0.340.510.370.260.820.230.26-0.050.160.310.33-0.050.150.18-0.490.16
0.250.460.9-0.830.840.860.390.850.89-0.450.540.710.89-0.060.560.890.370.970.480.280.360.830.03-0.430.16
Click cells to compare fundamentals

Oramed Pharmaceuticals Account Relationship Matchups

Oramed Pharmaceuticals fundamental ratios Accounts

202120222023202420252026 (projected)
Other Current Liab(1.4M)(191K)1.4M1.5M1.7M1.8M
Retained Earnings(114.9M)(163.1M)(157.6M)(176.6M)(159.0M)(151.0M)
Total Liab11.5M10.5M57.7M9.9M11.4M9.3M
Common Stock424K476K485K480K552K579.6K
Total Assets128.0M161.6M220.6M155.3M178.6M187.5M
Net Debt(76.7M)(39.6M)42.6M(54.0M)(48.6M)(46.2M)
Accounts Payable2.6M2.2M551K789K907.4K824.5K
Cash77.2M40.5M9.1M54.4M62.6M65.7M
Other Current Assets1.2M1.4M537K1.3M1.5M1.6M
Total Current Assets95.3M157.1M162.6M143.2M164.7M172.9M
Short Term Debt130K247K51.3M216K248.4K236.0K
Net Invested Capital115.8M151.8M214.8M146.3M168.2M145.5M
Capital Stock424K476K485K480K552K472.8K
Net Working Capital88.7M151.4M109.4M137.5M158.2M115.0M
Today, most investors in Oramed Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oramed Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oramed Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.013

At this time, Oramed Pharmaceuticals' Price Earnings To Growth Ratio is relatively stable compared to the past year.

Oramed Pharmaceuticals February 17, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Oramed Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oramed Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oramed Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Oramed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oramed Pharmaceuticals's daily price indicators and compare them against related drivers.

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.